sb 203580 has been researched along with Diabetes, Gestational in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, SR; Cawyer, CR; Horvat, D; Jones, RO; Kuehl, TJ; Leonard, D; Uddin, MN; Zawieja, DC | 1 |
1 other study(ies) available for sb 203580 and Diabetes, Gestational
| Article | Year |
|---|---|
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Topics: Antigens, CD; Diabetes, Gestational; Endoglin; Enzyme-Linked Immunosorbent Assay; Female; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Imidazoles; Interleukin-6; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Placenta Growth Factor; Plasminogen Activator Inhibitor 1; Polymerase Chain Reaction; PPAR gamma; Pregnancy; Pregnancy Proteins; Pyridines; Receptors, Cell Surface; Rosiglitazone; Signal Transduction; Thiazolidinediones; Trophoblasts; Urokinase-Type Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2014 |